Vitae Pharmaceuticals Inc (VTAE): RA Capital Management Ups Its Stake

Page 3 of 7 – SEC Filing

CUSIP No. 92847N103 13G

1.

Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

Peter Kolchinsky


2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨

3. SEC Use Only

4. Citizenship or Place of Organization         United States

Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
5. Sole Voting Power                         0

6. Shared Voting Power              2,119,036

7. Sole Dispositive Power                 0

8. Shared Dispositive Power       2,119,036

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

2,119,036


10.

Check if the Aggregate
Amount in Row (9) Excludes Certain Shares (See Instructions)
    ¨


11.

Percent of Class Represented by Amount in Row (9)

7.3%2


12.

Type of Reporting Person (See Instructions)

IN


2
The reporting person is the beneficial owner of 2,119,036 shares of Common Stock which constitutes approximately 7.3% of the Issuer’s
outstanding Common Stock shares. The percentage calculation assumes that there are currently 28,841,067 outstanding Common Stock
shares of the Issuer, based on the Issuer’s 10-Q as filed with the Securities and Exchange Commission (“SEC”)
on July 29, 2016.

Follow Vitae Pharmaceuticals Inc (NASDAQ:VTAE)